{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-036589","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.422954+00:00","generated_at":"2026-05-31T10:01:51.813370+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avalo Therapeutics reports net loss of $22.8M in H1 2024; cash $93.4M; AVTX-009 Phase 2 enrollment on track for H2","bullets":["Cash and cash equivalents $93.4M as of June 30, 2024; expected cash runway into 2027.","Net loss for six months ended June 30, 2024 was $22.8M, compared to $18.1M in same period 2023.","AVTX-009 IND for hidradenitis suppurativa active; Phase 2 LOTUS Trial first patient enrollment expected H2 2024.","Appointed Dr. Mittie Doyle as CMO and Paul Varki as CLO; Q2 2024 net income of $98.5M from warrant liability fair value change."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-036589","json":"https://secwatch.observer/filing/0001628280-24-036589.json","markdown":"https://secwatch.observer/filing/0001628280-24-036589.md","text":"https://secwatch.observer/filing/0001628280-24-036589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024036589/0001628280-24-036589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024036589/avtx-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:01:51.813370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}